|
|||||
|
|

Water technology company Xylem (NYSE:XYL) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 6.1% year on year to $2.30 billion. The company’s full-year revenue guidance of $8.95 billion at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $1.26 per share was 9.9% above analysts’ consensus estimates.
Is now the time to buy XYL? Find out in our full research report (it’s free).
Xylem delivered a well-received second quarter, with the market responding positively to strong execution and outperformance versus Wall Street expectations. Management attributed the results primarily to broad-based organic growth across its business units—especially in measurement and control solutions—and robust demand for advanced metering and treatment solutions. CEO Matthew Pine emphasized that productivity initiatives, supply chain actions, and targeted pricing more than offset the impact of tariffs and inflation. Pine highlighted, “Our pricing and supply chain actions more than offset inflation and tariff-related costs,” underscoring the value of operational discipline and simplification efforts in enhancing both margins and customer responsiveness.
Looking ahead, Xylem’s updated guidance is underpinned by continued strength in orders, a resilient backlog, and confidence in its ongoing operational transformation. Management believes that further gains will be supported by productivity improvements, the integration of recent acquisitions, and sustained growth in key end markets. CFO Bill Grogan noted that while tariff impacts and macro uncertainty remain, the company’s proactive pricing strategies and supply chain adjustments are expected to substantially offset these pressures. Pine added, “We remain focused on executing the plan we laid out at Investor Day last year,” signaling a commitment to both near-term delivery and long-term value creation.
Management credited second quarter momentum to operational simplification, healthy end-market demand, and successful integration of recent acquisitions, while noting that pricing actions and productivity offset headwinds from tariffs and inflation.
Xylem’s outlook for the rest of the year is shaped by sustained demand in key segments, ongoing benefits from operational simplification, and the integration of recent acquisitions, all while navigating tariff and macroeconomic uncertainties.
In the coming quarters, our analysts will watch (1) the pace at which Xylem’s measurement and control solutions segment recovers as destocking and replacement cycles progress, (2) further improvements in operating margins from continued simplification and the roll-off of legacy projects, and (3) the successful integration and scaling of recent niche acquisitions in advanced water treatment. Developments in tariffs, supply chain adjustments, and U.S. infrastructure funding will also be important indicators of execution and resilience.
Xylem currently trades at $143.43, up from $130.69 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Nov-04 | |
| Oct-30 | |
| Oct-30 | |
| Oct-29 | |
| Oct-29 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite